Your session is about to expire
← Back to Search
EphB4-HSA + Pembrolizumab for Cancer
Study Summary
This trial is studying a combination of a protein and an antibody to treat patients with non-small cell lung or head and neck squamous cell cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.I have an active tuberculosis infection.You have an active hepatitis B or C infection.My kidney function is within the normal range or slightly above.My blood clotting time is normal or managed with medication.I am a man who can father a child and will use birth control during and for 4 months after the study.I have not received a live vaccine in the last 30 days.Women who can have children should have a negative pregnancy test before starting the study treatment. If the urine test is positive or not clear, a blood test will be needed.I have had up to 2 chemotherapy treatments before.I have refused first-line platinum-based chemotherapy.My cancer returned within 6 months after treatment with cisplatin.Your absolute neutrophil count is at least 1,500 per microliter.I am currently being treated for an infection.I agree to use birth control during and up to 120 days after the study.I am fully active or restricted in physically strenuous activity but can do light work.I have been treated with specific immune system targeting drugs before.I haven't had cancer treatment with a monoclonal antibody in the last 4 weeks or have recovered from its side effects.I have stable brain metastases, not on steroids for 7 days, and no new brain growths.I have a history of or currently have non-infectious lung inflammation.I agree to provide a tissue sample from my tumor after 2 treatment cycles.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.My lung cancer has worsened after chemotherapy.My cancer progressed despite treatment with specific targeted therapy.My head or neck cancer got worse after platinum-based treatment.My cancer has returned or spread to other parts of my body.You are allergic to pembrolizumab or any of the ingredients in it.My blood clotting time is normal or managed if I'm on blood thinners.Your albumin level in the blood is at least 2.5 mg/dL.I haven't had cancer treatment in the last 2 weeks or I've recovered from its side effects.You have a measurable tumor according to specific guidelines.My hemoglobin level is above 9 g/dL without needing transfusions or EPO recently.Your AST and ALT levels in your blood are not too high.I have been diagnosed with HIV.You have enough platelets in your blood (at least 100,000 per microliter).I have another cancer, but it's either not growing or doesn't need treatment, except for certain skin cancers or cervical cancer that's been treated.Your bilirubin levels in the blood should not be too high.
- Group 1: Treatment (pembrolizumab, sEphB4-HSA)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What maladies has Recombinant EphB4-HSA Fusion Protein been employed to address?
"Recombinant EphB4-HSA Fusion Protein is often prescribed to treat malignant neoplasms and other medical issues, such as advanced melanoma, high microsatellite instability levels, or disease progression after chemotherapy."
What potential hazards should be considered when using Recombinant EphB4-HSA Fusion Protein?
"According to our internal assessment, Recombinant EphB4-HSA Fusion Protein has been rated as a 2 on the scale of 1 to 3. This is due to this being a Phase 2 trial with some evidence supporting its safety but not yet any efficacy data."
Are there still opportunities for participation in this clinical experiment?
"At this time, participation in the trial is not being accepted. The research was first posted on March 10th of 2017 and last updated November 18th 2022. For those searching for other opportunities to participate, 5068 clinical trials are recruiting patients with malignant neoplasms and 965 studies require participants who will receive Recombinant EphB4-HSA Fusion Protein treatment."
Are there any historical precedents of employing Recombinant EphB4-HSA Fusion Protein in clinical trials?
"At this time, the research of Recombinant EphB4-HSA Fusion Protein has been taken on by 965 studies. Of these investigations, 122 have advanced to Phase 3 trials. Despite a concentration in Houston, Texas - 35744 other sites are conducting studies for this medicinal intervention."
What is the overall participant count of this experiment?
"At this moment in time, no new candidates are being accepted for this clinical trial. Initially posted on 3/10/2017 and last edited on 11/18/2022, the study is currently dormant. If you're looking to participate in other trials related to malignant neoplasms there's 5068 studies actively enrolling participants while 965 seek people willing to try Recombinant EphB4-HSA Fusion Protein treatments."
Share this study with friends
Copy Link
Messenger